Original research

- 1 Prediabetic Levels of Hyperglycemia as a Predictor of Microvascular
- 2 Angina with Possible Involvement of Low Levels of High-Density
- 3 Lipoprotein Cholesterol and Hemoglobin
- 4 5
- ⁶ Satoru Suzuki, MD, PhD^{1, 2, #}, Kenshi Yamanaga, MD, PhD^{1, #}, Masanobu Ishii, MD,
- ⁷ PhD^{1, #}, Erika Matsumoto, BS³, Naoto Kuyama, MD, PhD¹, Kyoko Hirakawa, MD,
- ⁸ PhD¹, Noriaki Tabata, MD, PhD¹, Tomonori Akasaka, MD, PhD¹, Koichiro Fujisue,
- ⁹ MD, PhD¹, Shinsuke Hanatani, MD, PhD¹, Yuichiro Arima, MD, PhD¹, Hiroki Usuku,
- ¹⁰ MD, PhD¹, Eiichiro Yamamoto, MD, PhD¹, Kentaro Oniki, PhD³, Hirofumi Soejima,
- ¹¹ MD, PhD¹, Junji Saruwatari, PhD³, Hiroaki Kawano, MD, PhD¹, Hideaki Jinnouchi,
- ¹² MD, PhD⁴, Koichi Kaikita, MD, PhD^{1,5}, Hirofumi Yasue, MD, PhD⁶, Hisao Ogawa,
- ¹³ MD, PhD⁷, Kenichi Tsujita, MD, PhD^{1,*}
- 14
- ¹⁵ ¹ Department of Cardiovascular Medicine and Center for Metabolic Regulation of Healthy
- Aging, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku,
- Kumamoto City 860-8556, Japan;
- ¹⁸ ² Department of Cardiovascular Medicine, National Hospital Organization Kumamotominami
- 19 National Hospital, 2338 Toyofuku, Matsubase-machi, Uki City, Kumamoto Prefecture
- 20 **869-0593**, Japan;
- ³ Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences,
- Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto City, 862-0973, Japan;
- ⁴ Diabetes Center, Jinnouchi Hospital, 6-2-3 Kuhonji, Chuo-ku, Kumamoto City 862-0976,
- 24 Japan;
- ⁵ Division of Cardiovascular Medicine and Nephrology, Department of Internal Medicine,
- ²⁶ Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki City
- 27 **889-1692**, Japan;
- ⁶ Division of Cardiovascular Medicine, Kumamoto Kinoh Hospital, Kumamoto Aging
- 29 Research Institute, 6-8-1 Yamamuro, Kita-ku, Kumamoto City 860-8518, Japan;
- ³⁰ ⁷ Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto City 860-8555, Japan.
- 31
- ³² [#] Satoru Suzuki, Kenshi Yamanaga, and Masanobu Ishii contributed equally to this article.
- 33

- ¹ *Corresponding author information: Kenichi Tsujita, MD, PhD, Department of
- 2 Cardiovascular Medicine and Center for Metabolic Regulation of Healthy Aging, Graduate
- 3 School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto City
- 4 860-8556, Japan. Phone: +81-96-373-5175, Fax: +81-96-362-3256, E-mail:
- 5 tsujita@kumamoto-u.ac.jp
- 6
- 7 Total word count: 2833 words in the text, and 293 words in the abstract
- 8 Total number of figures and tables: 1 figure and 7 tables

1 Abstract

2	Background: The management of modifiable risk factors, including conventional risk factors,
3	can play an important role in the treatment for microvascular angina (MVA). The purpose of
4	this study was to clarify the clinical characteristics of MVA in a case-control study, thereby
5	elucidating the pathogenesis and management of MVA.
6	Methods: This study enrolled 92 consecutive patients with MVA (39 men, 53 women, mean
7	age 63.2 \pm 12.1 years) without obstructive coronary artery disease (\geq 50% stenosis) or
8	acetylcholine-provoked epicardial coronary spasms between 1993 and 2015. This study
9	enrolled 691 age-matched Japanese participants (466 men, 225 women, mean age 62.9 ±11.0
10	years) without a history of chest pain or cardiovascular diseases between 2006 and 2012 as
11	controls.
12	Results: In multivariate logistic regression analysis, elevated haemoglobin A1c (HbA1c) (per
13	1 mmol/mol), low high-density lipoprotein cholesterol (HDL-C) (per 1mmol/L), and low
14	haemoglobin (Hgb) (per 10×g/L) levels were significantly associated with MVA (odds ratio
15	[OR] 1.07[1.04-1.10], p <0.001; OR 0.13[0.06-0.29], p <0.001; OR 0.56[0.44-0.72], p <0.001,
16	respectively). However, the difference between the prevalence of diabetes in MVA patients vs.
17	the prevalence in controls was not significant. MVA patients without diabetes had significantly
18	higher HbA1c levels than control patients without diabetes (39±4 mmol/mol vs. 34±3
19	mmol/mol, respectively; p <0.001). These results were also true for patients and controls

1	stratified by sex. A higher prevalence of proteinuria and lower mean corpuscular volume of
2	erythrocytes were found in MVA patients than in controls stratified by sex.
3	Conclusions: Hyperglycaemia reflected by mildly elevated HbA1c levels, (i.e., prediabetes)
4	may be a risk factor for MVA. Low levels of HDL-C and Hgb may also be risk factors for
5	MVA. MVA could be one of the systemic manifestations of microvascular diseases. The
6	study may aid in identifying high-risk MVA patients, allowing increased monitoring and
7	treatments for them.
8	
9	
10	Section head: Coronary artery disease
11	
12	
13	Key words: Microvascular angina, Coronary microvascular dysfunction, Glycated
14	Haemoglobin, High-density lipoprotein cholesterol, Haemoglobin
15	
16	
17	Research checklist : STROBE checklist: case-control studies

1 What is already known on this topic:

2	Microvascular angina (MVA) has been attracting attention of clinical research because MVA can
3	be associated with future cardiovascular events. The management of modifiable risk factors,
4	including conventional risk factors, can play an important role in the treatment of MVA because
5	there is currently no specific treatment of MVA. The purpose of this study was to clarify the
6	clinical characteristics of MVA.
7	
8	What this study adds:
9	Hyperglycaemia reflected by mildly elevated haemoglobin A1c levels, (i.e., prediabetes) may be
10	a risk factor for MVA. Low levels of high-density lipoprotein cholesterol and haemoglobin
11	may also be risk factors for MVA. A higher prevalence of proteinuria and lower mean
12	corpuscular volume of erythrocytes were found in MVA patients than in controls stratified by
13	sex.
14	
15	How this study might affect research, practice or policy:

MVA could be one of the systemic manifestations of microvascular diseases. The study findings may aid in identifying high-risk patients with MVA, allowing increased monitoring and treatments for them.

1 Introduction

2	Patients with suspected angina are frequently found to have non-obstructive coronary
3	artery disease (CAD). This condition has recently been called "ischaemia with
4	non-obstructive CAD (INOCA)" ¹⁻⁵ . Non-acetylcholine (ACh)-provoked epicardial coronary
5	spasm is sometimes seen in patients with INOCA. A possible cause of this can be
6	microvascular angina (MVA) due to coronary microvascular dysfunction (CMD). MVA has
7	been a recent focus of clinical research because MVA has emerged as an important factor
8	associated with adverse cardiovascular outcomes ^{1 2 6 7} . However, the pathogenesis and
9	management of MVA remain unknown.
10	Previous studies have found that ageing, smoking, hypertension (HT), diabetes mellitus
11	(DM), and dyslipidaemia (DLP) could be associated with MVA ⁸⁻¹⁰ . In contrast, other studies
12	have found that DM was uncommon in patients with angina and non-obstructive CAD,
13	whereas HT and DLP were relatively common ^{11 12} . Thus, the association between
14	conventional cardiovascular risk factors and MVA has not yet been established ⁴ . The
15	management of modifiable risk factors including conventional risk factors can play an
16	important role in the treatment of MVA, because there is currently no specific treatment of
17	MVA ^{4 13} .

The purpose of this study was to clarify the clinical characteristics of MVA in a case-control study, thereby elucidating the pathogenesis and management of MVA.

1 Methods

2 Study patients and definition of MVA

3	We retrospectively enrolled 92 consecutive Japanese patients with MVA (39 men, 53
4	women) who were admitted to our institution for coronary angiography because of anginal
5	chest pain between January 1993 and December 2015 (figure 1). All vasoactive drugs,
6	including calcium channel blockers, nitrates, nicorandil, alpha-adrenergic blockers, and
7	beta-adrenergic blockers were discontinued \geq 48 hours before coronary angiography (CAG),
8	which included an ACh provocation test and a coronary flow reserve (CFR) measurement by
9	intravenous infusion of adenosine triphosphate (ATP). Every study patient underwent CAG
10	in the morning while fasting. After the ACh provocation test, isosorbide dinitrate (ISDN)
11	was infused into the left and right coronary arteries, followed by examining the epicardial
12	coronary artery for stenosis.
13	The diagnosis of MVA was based on satisfying all the criteria for MVA proposed by the
14	Coronary Vasomotion Disorders International Study Group (COVADIS), as follows: (1) signs
15	and/or symptoms of myocardial ischaemia, (2) absence of obstructive CAD (≥50% stenosis)
16	by CAG, (3) objective evidence of myocardial ischaemia (i.e., chest pain and ischaemia on
17	ECG) with non-epicardial coronary spasm by an ACh-provocation test, and (4) evidence of
18	impaired coronary microvascular function (CFR <2.0 by invasive measurement or
19	non-epicardial coronary spasm during an ACh-provocation test) ¹⁴ .

1	Study exclusion criteria were as follows: decompensated heart failure, cardiomyopathy,
2	severe valvular heart disease, a previous history of coronary artery revascularization, and
3	obstructive CAD (≥50% stenosis). Patients were also excluded for a diagnosis of epicardial
4	coronary spasm that was based on JCS/CVIT/JCC 2023 Guideline Focussed Update on
5	Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary
6	Microvascular Dysfunction by the Japanese Circulation Society ¹ . In addition, patients were
7	excluded for other factors as follows: receiving haemodialysis; or having advanced chronic
8	obstructive pulmonary disease, advanced collagen disease, active inflammatory disease, severe
9	liver dysfunction, and/or neoplasms at the time of enrolment.
10	The control patients included 691 age-matched Japanese participants (466 men, 225
11	women) without a history of chest pain or cardiovascular diseases who underwent medical
12	examinations at the Japanese Red Cross Kumamoto Health Care Centre between January 2006
13	and April 2012.
14	
15	Measurement of coronary flow reserve
16	Before the ACh provocation test, we inserted a 0.014-inch guidewire that was equipped
17	with a Doppler velocity probe (FloWire; Philips Volcano, San Diego, CA) into the left anterior
18	descending coronary artery. After the ACh provocation test was followed by the
19	administration of intracoronary ISDN, ATP (150 μ g/kg/min) was administered via the central

vein until maximal hyperaemia was achieved to allow the calculation of haemodynamic
 parameters. When maximal coronary hyperaemia was attained, the FloWire was used to
 measure the CFR, as previously described ¹⁵.

4

5 Definition of risk factors for cardiovascular diseases

The conventional risk factors for cardiovascular diseases were defined as follows: 6 current smoking, HT (blood pressure ≥140/90 mmHg or taking anti-hypertensive drugs), DLP 7 (low-density lipoprotein cholesterol [LDL-C] \geq 3.6 mmol/L [140 mg/dL], high-density 8 lipoprotein cholesterol [HDL-C] <1.0 mmol/L [40 mg/dL], triglycerides [TG] \geq 1.7 mmol/L 9 [150 mg/dL] or taking lipid-lowering drugs), and DM (fasting plasma glucose levels \geq 7.0 10 mmol/L [126 mg/dL], >11.1 mmol/L [200 mg/dL] during a 75-g oral glucose tolerance test, or 11 taking anti-diabetic drugs). In regard to serum glycosylated haemoglobin A1c (HbA1c) 12 levels, until the end of March 2012, the measurements proposed by the Japan Diabetes Society 13 14 (JDS) were applied for study patients; whereas starting in April 2012, the measurements described by the National Glycohemoglobin Standardisation Programme (NGSP) were 15 adopted. In our study, the HbA1c levels (JDS) measured until March 2012 were adjusted to 16 the NGSP levels (i.e., HbA1c [NGSP] [%] =HbA1c [JDS] [%] +0.4)¹⁶. Additionally, the 17 HbA1c levels (NGSP) (%) were adjusted to the HbA1c levels (IFCC) (mmol/mol) (i.e., 18 HbA1c [IFCC] [mmol/mol] = 10.93 × HbA1c [NGSP] (%) -23.52). 19

1

2 Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or
dissemination plans of this research. We plan to disseminate the findings to participants and
the public.

6

7 Statistical analysis

8 Continuous values were expressed as means ± standard deviation (SD), whereas data 9 with a skewed distribution were expressed as medians (interquartile range). Continuous 10 variables were compared by two-tailed unpaired t-tests. A Mann-Whitney U test was 11 performed for continuous variables with a skewed distribution. Frequencies of clinical 12 variables stratified into two groups were compared by the Fisher exact test.

Clinical parameters were assessed by univariate and multivariate logistic regression analyses for significant association with MVA. The multivariate logistic regression analysis was used to evaluate parameters that were identified as statistically significant (p <0.05) by univariate logistic regression analysis, with the exclusion of redundant and/or missing data on the variables. We did not include 'DLP' in the multivariate logistic regression analysis because the correlation between 'DLP' and HDL-C levels was strong. The variables 'current smoking' and 'proteinuria' were not included in the multivariate logistic regression analysis

because there were only a few patients who were current smokers or had proteinuria (tables

2 **3-5**).

- 3 Stata version 18 (Stata Corp., College Station, TX, USA) and BellCurve for Excel,
- ⁴ version 4.06 (Social Survey Research Information Co., Ltd., Tokyo, Japan) were used for
- 5 statistical analysis. Statistical significance was defined as a p-value < 0.05.

1 Results

2 Clinical characteristics

3	Table 1 shows the clinical characteristics of 92 (39 men, 53 women) patients with MVA
4	and 691 (466 men, 225 women) control participants. The patients with MVA had a
5	significantly lower prevalence of DLP; higher HbA1c, lower HDL-C, higher CRP, and lower
6	Hgb levels; and a higher prevalence of proteinuria than the control participants.
7	Table 2 shows the clinical characteristics of MVA patients and control participants
8	stratified by sex. The men patients with MVA had significantly higher HbA1c, lower HDL-C,
9	and lower Hgb levels; and a higher prevalence of proteinuria than the control participants.
10	The women patients with MVA had significantly higher HbA1c, lower HDL-C, higher TG,
11	higher CRP, higher WBC, and lower Hgb levels; and higher prevalence of current smoking,
12	and higher prevalence of proteinuria than the control participants.
13	
14	Univariate and multivariate logistic regression analysis of characteristics associated with
15	MVA
16	Table 3 shows the results of univariate and multivariate logistic regression analysis for
17	the association of variables with MVA. Univariate logistic regression analysis showed that
18	women, HT, DLP, HbA1c, HDL-C, Hgb, and proteinuria were all significantly associated with
19	MVA. Multivariate logistic regression analysis showed that HbA1c, HDL-C, and Hgb were

significantly associated with MVA.

2	Table 4 shows the results of univariate and multivariate logistic regression analysis for
3	MVA in men. Univariate logistic regression analysis showed that HbA1c, HDL-C, Hgb, and
4	proteinuria were all significantly associated with MVA. Multivariate logistic regression
5	analysis showed that HbA1c, HDL-C, and Hgb were significantly associated with MVA.
6	Table 5 shows the results of univariate and multivariate logistic regression analysis for
7	MVA in women. Univariate logistic regression analysis showed that current smoking,
8	HbA1c, HDL-C, CRP, WBC, Hgb, and proteinuria were all significantly associated with MVA.
9	Multivariate logistic regression analysis showed that HbA1c, HDL-C, WBC, and Hgb were
10	significantly associated with MVA.
11	

12 Erythrocyte indices of MVA in men and women

Table 6 compares the erythrocyte indices between patients with MVA and control participants stratified by sex. Men with MVA had a significantly lower Hgb level and lower mean corpuscular volume (MCV) than the control men. Women with MVA had a significantly lower Hgb level, lower MCV, and a lower serum iron level than the control women.

18

19 Clinical characteristics of patients with MVA stratified by CFR <2.0 and CFR ≥2.0

1	Table 7 shows the clinical characteristics of CFR <2.0 and CFR \ge 2.0 in 55 MVA
2	patients whose CFRs were measured amongst 92 MVA patients. CFR \geq 2.0 was more
3	common in women with MVA than in men with MVA (29/35 [83%] vs. 9/20 [45%], p =0.006).

1 Discussion

2	This case-control study investigated the clinical characteristics of patients with MVA.
3	The major findings were as follows: (1) amongst 92 MVA patients, 39 were men (42%) and 53
4	were women (58%) (table 1 and figure 1); (2) elevated HbA1c, low HDL-C, and low Hgb
5	levels were significantly associated with MVA in men and women (tables 4-5); (3) proteinuria
6	was more common in men and women patients with MVA than in the control men and women,
7	respectively (table 2); (4) MCV was significantly lower in men and women patients with MVA
8	than in the control men and women, respectively (table 6); (5) in patients with MVA, a CFR
9	\geq 2.0 was more common in women than in men (table 7). To the best of our knowledge, this
10	study is the first to report that elevated HbA1c, low HDL-C, and low Hgb levels were
11	significantly associated with MVA, and a CFR \geq 2.0 was more common in women with MVA
12	than in men with MVA.
13	The mechanisms of CMD, which is the cause of MVA, are multifactorial and result from

¹⁴ functional or structural abnormalities in the coronary microvasculature, including (1) ¹⁵ increased vasoconstriction, (2) impaired coronary vasodilator capacities, and (3) increased ¹⁶ coronary microvascular resistance, all three of which can occur alone or in combination ¹. In ¹⁷ this study, we enrolled 92 consecutive Japanese patients with MVA who underwent ¹⁸ comprehensive evaluation of coronary microvascular function that consisted of cardiac ¹⁹ catheterisation with an ACh provocation test and CFR measurements (interventional

diagnostic procedure) to assess CMD. We evaluated the clinical characteristics of the MVA
 patients.

3	This study showed that an elevated HbA1c level was significantly associated with MVA.
4	This result was true for both men and women (tables 3-5). The mean HbA1c levels in MVA
5	patients were 44±11 mmol/mol, 43±11 mmol/mol, and 44±11 mmol/mol in men+women, men,
6	and women, respectively, which are not severely hyperglycaemic levels (tables 1-2). Some
7	reports have shown that diabetic microvascular diseases, such as retinopathy or nephropathy,
8	can precede the appearance of type 2 diabetes, and may contribute to the development of
9	micro-/macro-vascular complications in patients with type 2 DM, prediabetes, or
10	hyperglycaemia ^{17 18} . Another study has shown that proteinuria in prediabetes might be an
11	early biomarker for detectable diabetic nephropathy ¹⁹ . This study found no differences of
12	the prevalence rates of DM between the patients with MVA and the control participants.
13	However, in this study, the number of proteinuria was significantly higher in patients with
14	MVA than in the control participants. The HbA1c levels excluding DM patients were
15	significantly higher in patients with MVA than in the control participants. (tables 1-2). These
16	findings suggested that hyperglycaemia reflected by mildly elevated HbA1c levels such as in
17	patients with prediabetes could be critically involved in the development of MVA.
18	Hyperglycaemia may contribute to microvascular diseases by the suppression of
19	endothelium-dependant vasodilation through the increased production of free radicals ¹³ .

Therefore, microvascular diseases associated with hyperglycaemia, as reflected by mildly elevated HbA1c levels (i.e., prediabetes), could represent systemic phenomena that extend beyond pathologic manifestations such as nephropathy to the coronary circulation. Mildly elevated HbA1c levels could be a critical marker for MVA.

This study showed that a low Hgb level was significantly associated with MVA. This 5 result was true for both men and women (tables 3-5). A previous paper reported that reduced 6 haemoglobin could predict adverse outcomes in patients with ischaemic heart disease not only 7 through reduced oxygen delivery but also through reduced nitric oxide availability ²⁰. In this 8 study, although the Hgb levels did not satisfy the criterion for anaemia, Hgb and MCV levels 9 were significantly lower in patients with MVA than in control participants, in both men and 10 women (table 6). The serum iron level was significantly lower in the MVA women patients 11 than in the control women. By contrast, the difference between the ferritin levels in MVA 12 women patients and control women was not significant. Based on these observations, 13 14 haematopoietic dysfunction caused by an iron disorder could be associated with MVA, although the aetiology could not be clarified by the available data in this study. 15

This study found that a low HDL-C level was significantly associated with MVA in both men and women (tables 4-5). Low HDL-C is an established risk factor not only for macrovascular events, but also for microvascular diseases in diabetic patients ²¹. The underlying mechanisms involved in the macrovascular and microvascular diseases in diabetes

1	have been found to be the association of low HDL-C levels with increased oxidative stress,
2	increased inflammation, and dysfunctional endothelium ²² . Another study has shown that
3	HDL-C could be a factor involved in reduced CFR ⁸ . Based on these findings altogether, low
4	HDL-C could be associated with MVA.
5	In this study, of 55 patients with MVA who underwent CFR measurement, a CFR ≥ 2.0
6	was more common in women than in men (29 women with CFR ≥ 2.0 [29/35 =83%] vs. 9
7	women with CFR <2.0 [9/20 =45%], p =0.006) (table 7). MVA patients with a CFR \geq 2.0 had
8	ischaemic findings during anginal symptoms and on ECG without epicardial coronary spasms
9	by the ACh provocation test. The results suggested that these patients might have coronary
10	microvascular spasms, although coronary microvascular spasms cannot be directly visualised.
11	Our finding that coronary microvascular spasm was more common in women than in men was
12	consistent with the findings of previous studies 2324 . In our study, the women with MVA and
13	a CFR \geq 2.0 were aged 62.5 ±11.4 years (data not shown), which suggested that many of them
14	were postmenopausal and had oestrogen deficiency. Oestrogen can modulate coronary
15	microvascular vasomotor function ¹³ . There are several types of MVA, which include
16	increased vasoconstriction (microvascular spasm), impaired vasodilator capacity, and
17	increased resistance ¹ . The different types of MVA might be sex specific. Further studies
18	on the association of MVA subtypes with the sex of study patients are needed.

19

MVA can be detected in 30% to 50% of patients with anginal symptoms and

1	nonobstructive CAD on invasive CAG ^{5 14} . CMD leading to MVA can play an important role
2	not only in angina, but also in various cardiovascular diseases such as acute coronary
3	syndrome and left ventricular hypertrophy ^{13 25} . Patients with anginal symptoms and
4	angiographically nonobstructive CAD currently have large burdens of cardiovascular disease,
5	including repeated hospitalisations and CAG, which also indicate that the economic burden of
6	MVA is increasing ²⁶ . The majority of MVA patients remain undertreated because of the lack
7	of evidence-based data. This study showed that hyperglycaemia as reflected by mildly
8	elevated HbA1c levels, and low HDL-C and Hgb levels were significantly associated with
9	MVA, and that a CFR \geq 2.0 was more common in women than in men patients with MVA.
10	Because there is currently no specific treatment for MVA, the management of modifiable risk
11	factors, including conventional risk factors, can play an important role in the treatment of
12	MVA ⁴¹³ . Therefore, our observational findings may be helpful for further risk stratification
13	and the development of treatment strategies for MVA.

14

16

17

18

19

15 Study Limitations

This study has several limitations. First, it was a single-centre study with a relatively small sample size. Second, it was a retrospective study. Third, the study only included Japanese patients and participants. Fourth, our results may not be applicable to patients who are outside of the age range we studied. Fifth, the control group comprised 691 age-matched

1	Japanese participants (466 men, 225 women) without a history of either chest pain or
2	cardiovascular diseases. We did not have any information on the medications taken by the
3	control participants. Moreover, we could not completely rule out that a control participant
4	might have asymptomatic CAD. Sixth, we did not measure CFR in all the study patients and
5	all the control participants. Further analyses and recalibrations of a larger and independent
6	study population are needed.

1 Conclusions

2	Hyperglycaemia reflected by mildly elevated HbA1c levels, (i.e., prediabetes) may be a
3	risk factor for MVA. Low HDL-C and low Hgb levels may also be risk factors for MVA.
4	CFR \geq 2.0 was more common in women than in men amongst MVA patients. MVA could be
5	a systemic phenomenon associated with microvascular diseases. The study findings may aid
6	in identifying high-risk patients with MVA, allowing increased monitoring and treatments for
7	them.

1 Contributions

2	SS, KY, MI, HY, HO, and KT designed the study. SS, KY, MI, EM, NK, KH, NT, TA, KF,
3	SH, KO, JS, and KT collected the data. SS, KY, MI, YA, HU, EY, KO, and JS carried out the
4	statistical analyses and interpreted the data results. SS, KY, MI, and HY wrote the
5	manuscript. EY, HS, HK, HJ, KK, HY, HO, and KT supervised the project. SS, KY, and
6	MI contributed equally to this article. All authors read and approved the final manuscript.
7	
8	Funding
9	Not applicable.
10	
11	Competing interests
12	Dr. Hisao Ogawa has received remuneration for lectures from AstraZeneca, Bayer Yakuhin,
13	Ltd., Daiichi Sankyo Co., Ltd., Eisai, Kowa Pharmaceutical Co. Ltd., Takeda Pharmaceutical
14	Co., Ltd., Teijin Pharma, JSR, Nxera Pharma. Dr. Koichi Kaikita received grants from
15	Grants-in-Aid for Scientific Research (23K07534) from the Ministry of Education, Culture,
16	Sports, Science and Technology of Japan; received remuneration for lecture from Bayer
17	Yakuhin, Ltd., Daiichi-Sankyo Co., Ltd., Novartis Pharma AG., Otsuka Pharmaceutical Co.,
18	Ltd., Bristol-Myers K.K., and Kowa Pharmaceutical Co. Ltd.; received trust research/joint
19	research funds from Bayer Yakuhin, Ltd., and Daiichi-Sankyo Co., Ltd.; and received

1	scholarship fund from Abbott Medical Co., Ltd. Dr. Kenichi Tsujita has received
2	remuneration for lectures from Abbott Medical Co., Ltd, Amgen K.K., Bayer Yakuhin, Ltd.,
3	Daiichi Sankyo Co., Ltd., Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co.,
4	Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co.,Ltd., Pfizer Japan Inc., Takeda
5	Pharmaceutical Co., Ltd., and TERUMO Co, Ltd.; has received trust research/joint research
6	funds from Bayer Yakuhin, Ltd., Bristol-Myers K.K., Daiichi Sankyo Co., Ltd., MOCHIDA
7	PHARMACEUTICAL CO., LTD., Novo Nordisk Pharma Ltd., and PRA Health Sciences.; has
8	received scholarship fund from Abbott Medical Co., Ltd., ITI Co., Ltd., Boehringer Ingelheim
9	Japan, Otsuka Pharmaceutical Co., Ltd., and Boston Scientific Japan K.K.; has received
10	Affiliation with Endowed Department from Abbott Japan Co., Ltd., Boston Scientific Japan
11	K.K., Fides-one, Inc., GM Medical Co., Ltd., ITI Co., Ltd., Kaneka Medix Co., Ltd., NIPRO
12	CORPORATION, TERUMO Co, Ltd., Philips Japan Ltd., Getinge Group Japan K.K.,
13	Orbusneich Medical K. K, Abbott Medical Co., Ltd., BIOTRONIK JAPAN, INC, Boston
14	Scientific Japan K.K., Fukuda Denshi Co., Ltd., Japan Lifeline Co., Ltd., Medtoronic Japan
15	Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and NIPRO CORPORATION.
16	
17	Patient and public involvement

18 Patients and/or the public were not involved in the design, or conduct, or reporting, or

19 dissemination plans of this research.

1

2 Patients consent for publication

- ³ Not applicable.
- 4

5 Ethics approval

6	This study was conducted in accordance with the principles contained in the Declaration of
7	Helsinki. The protocol of our study was approved by the ethics committee of the Faculty of
8	Life Sciences, Kumamoto University, and the Japanese Red Cross Kumamoto Hospital Health
9	Care Centre (approval number: 473). We obtained a signed informed consent from each
10	patient and participant. This study is registered at the University Hospital Medical
11	Information Network (UMIN) Clinical Trials Registry (UMIN 000043834). Opt-out
12	materials are available through the website: https://kumadai-junnai.com/archives/clinical.
13	
14	Provenance and peer review
15	Not commissioned; externally peer reviewed.

16

17 **Data availability statement**

¹⁸ The data that support the findings of this study are available upon reasonable request.

19

1 Acknowledgement

2 We thank Michiyo Saito, MT, at our institution for her excellent technical assistance.

3

4 ORCID iDs

- 5 Satoru Suzuki https://orcid.org/0000-0001-5545-143X
- 6 Masanobu Ishii https://orcid.org/0000-0003-4137-9136
- 7 Yuichiro Arima https://orcid.org/0000-0002-9840-3347
- 8 Eiichiro Yamamoto https://orcid.org/0000-0002-9072-0348
- 9 Kenichi Tsujita https://orcid.org/0000-0002-4314-259X

1 References

2	1	Hokimoto S, Kaikita K, Yasuda S, et al. JCS/CVIT/JCC 2023 Guideline Focused
3		Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina)
4		and Coronary Microvascular Dysfunction. Circ J 2023;87:879-936.
5	2	Perera D, Berry C, Hoole SP, et al. Invasive coronary physiology in patients with
6		angina and non-obstructive coronary artery disease: a consensus document from the
7		coronary microvascular dysfunction workstream of the British Heart
8		Foundation/National Institute for Health Research Partnership. Heart 2022;109:88-95.
9	3	Suzuki S, Kaikita K, Yamamoto E, et al. Role of acetylcholine spasm provocation test
10		as a pathophysiological assessment in nonobstructive coronary artery disease.
11		Cardiovasc Interv Ther 2021;36:39-51.
12	4	Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on
13		Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European
14		Society of Cardiology Working Group on Coronary Pathophysiology &
15		Microcirculation Endorsed by Coronary Vasomotor Disorders International Study
16		Group. Eur Heart J 2020;41:3504-20.
17	5	Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and
18		Management of Patients With Myocardial Infarction in the Absence of Obstructive
19		Coronary Artery Disease: A Scientific Statement From the American Heart Association.
20		Circulation 2019;139:e891-e908.
21	6	Shimokawa H, Suda A, Takahashi J, et al. Clinical characteristics and prognosis of
22		patients with microvascular angina: an international and prospective cohort study by
23		the Coronary Vasomotor Disorders International Study (COVADIS) Group. Eur Heart
24		J 2021;42:4592-600.
25	7	Ohba K, Sugiyama S, Sumida H, et al. Microvascular coronary artery spasm presents

26

1		distinctive clinical features with endothelial dysfunction as nonobstructive coronary
2		artery disease. J Am Heart Assoc 2012;1:e002485.
3	8	Mygind ND, Michelsen MM, Pena A, et al. Coronary Microvascular Function and
4		Cardiovascular Risk Factors in Women With Angina Pectoris and No Obstructive
5		Coronary Artery Disease: The iPOWER Study. J Am Heart Assoc 2016;5:e003064.
6	9	Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to
7		adenosine predicts adverse outcome in women evaluated for suspected ischemia results
8		from the National Heart, Lung and Blood Institute WISE (Women's Ischemia
9		Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825-32.
10	10	Zeiher AM, Schächinger V, Minners J. Long-term cigarette smoking impairs
11		endothelium-dependent coronary arterial vasodilator function. Circulation
12		1995;92:1094-100.
13	11	Chhabra L, Kowlgi NG. Low Incidence of Diabetes Mellitus in Coronary
14		Microvascular Dysfunction: An Intriguing Association. JACC Cardiovasc Interv
15		2016;9:395-6.
16	12	Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of Coronary Microvascular
17		Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery
18		Disease. JACC Cardiovasc Interv 2015;8:1445-53.
19	13	Crea F, Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular
20		Dysfunction. Circ J 2022;86:1319-28.
21	14	Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic
22		criteria for microvascular angina. Int J Cardiol 2018;250:16-20.
23	15	Yamanaga K, Tsujita K, Komura N, et al. Single-wire pressure and flow velocity
24		measurement for quantifying microvascular dysfunction in patients with coronary
25		vasospastic angina. Am J Physiol Heart Circ Physiol 2015;308:H478-84.

27

1	16	Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of
2		glycated hemoglobin in Japan: From Japan Diabetes Society to National
3		Glycohemoglobin Standardization Program values. J Diabetes Investig 2012;3:39-40.
4	17	Sörensen BM, Houben AJ, Berendschot TT, et al. Prediabetes and Type 2 Diabetes Are
5		Associated With Generalized Microvascular Dysfunction: The Maastricht Study.
6		Circulation 2016;134:1339-52.
7	18	Sabanayagam C, Liew G, Tai ES, et al. Relationship between glycated haemoglobin
8		and microvascular complications: is there a natural cut-off point for the diagnosis of
9		diabetes? Diabetologia 2009;52:1279-89.
10	19	Furukawa M, Onoue T, Kato K, et al. Prediabetes is associated with proteinuria
11		development but not with glomerular filtration rate decline: A longitudinal
12		observational study. Diabet Med 2021;38:e14607.
13	20	Andreotti F, Coluzzi G, Lavorgna A, et al. Relation between nitric oxide metabolites
14		and haemoglobin concentrations in patients with ischaemic heart disease. Heart
15		2007;93:255-7.
16	21	Toth PP, Simko RJ, Palli SR, et al. The impact of serum lipids on risk for
17		microangiopathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol
18		2012;11:109.
19	22	Li Z, Huang Q, Sun L, et al. Atherogenic Index in Type 2 Diabetes and Its Relationship
20		with Chronic Microvascular Complications. Int J Endocrinol 2018;2018:1765835.
21	23	Jansen TPJ, Elias-Smale SE, van den Oord S, et al. Sex Differences in Coronary
22		Function Test Results in Patient With Angina and Nonobstructive Disease. Front
23		Cardiovasc Med 2021;8:750071.
24	24	Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic
25		characteristics, and safety evaluation of intracoronary acetylcholine provocation testing

1		among 921 consecutive white patients with unobstructed coronary arteries. Circulation
2		2014;129:1723-30.
3	25	Tsujita K, Yamanaga K, Komura N, et al. Impact of left ventricular hypertrophy on
4		impaired coronary microvascular dysfunction. Int J Cardiol 2015;187:411-3.
5	26	Schumann CL, Mathew RC, Dean JL, et al. Functional and Economic Impact of
6		INOCA and Influence of Coronary Microvascular Dysfunction. JACC Cardiovasc
7		Imaging 2021;14:1369-79.
8		

1 Legends

- 2
- 3 Figure 1. Flow chart of patient enrollment
- 4 ACh, acetylcholine; CFR, coronary flow reserve.

	All	MVA	Control	
	(n =783)	(n =92)	(n =691)	p value
Age (years)	63.0±11.1	63.2±12.1	62.9±11.0	0.82
Sex (women) (%)	278 (36%)	53 (58%)	225 (33%)	< 0.001
BMI (kg/m ²)	23.2±3.1	23.3±3.7	23.1±3.0	0.55
Current smoking (%)	110 (14%)	16 (17%)	94 (14%)	0.34
HT (%)	307 (39%)	45 (49%)	262 (38%)	0.055
DM (%)	119 (15%)	19 (21%)	100 (14%)	0.16
DLP (%)	423 (54%)	40 (43%)	383 (55%)	0.034
eGFR (mL/min/1.73m ²)	73±14	74±18	73±13	0.41
Uric acid (µmol/L)	324±83	318±91	325±82	0.47
FPG (mmol/L)	5.6±1.0	5.4±1.7	5.6±0.9	0.12
HbA1c (mmol/mol)	38±9	44±11	37±8	< 0.001
HbA1c excluding DM patients	35±4	39±4	34±3	< 0.001
(mmol/mol)				
LDL-C (mmol/L)	3.1±0.7	3.0±0.9	3.1±0.7	0.050
HDL-C (mmol/L)	1.7±0.4	1.5±0.4	1.7±0.4	< 0.001
TG (mmol/L)	1.1 (0.8-1.5)	1.2 (0.9-1.6)	1.1 (0.8-1.5)	0.061
CRP (mg/L)	0.50 (0.30-1.00)	0.65(0.30-1.55)	0.50(0.30-1.00)	0.006
WBC (×10 ⁹ /L)	5.4±1.5	5.7±1.6	5.4±1.5	0.062
RBC (×10 ¹² /L)	4.59±0.42	4.29±0.44	4.63±0.40	< 0.001
Hgb (g/L)	144±14	132±14	146±13	< 0.001
Platelets ($\times 10^9$ /L)	210±49	213±58	210±47	0.54
Proteinuria (%)	16/656 (2%)	7/58 (12%)	9/598 (2%)	< 0.001
CFR		2.4±1.0 (n =55)	no data	
CFR ≥2.0 (%)		35/55 (64%)	no data	
Medications (on admission)				
ACE-I or ARB (%)		28 (30%)	no data	
CCB (%)		46 (50%)	no data	
Nitrate (%)		18 (20%)	no data	
Beta-blocker (%)		21 (23%)	no data	
Statin (%)		27 (29%)	no data	

Table 1. Clinical Characteristics of MVA Patients and Control Participants

Data are number of patients (%), means ± standard deviation (SD), and medians (interquartile

range). MVA, microvascular angina; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; CFR, coronary flow reserve; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

Table 2. Clinical Characteristics of MVA Patients and Control Participants in Men and

Women

	Men (n =505)			Women (n =278)		
	MVA (n =39)	Control (n =466)	p value	MVA (n =53)	Control (n =225)	p value
Age (years)	61.4±13.9	61.5±11.8	0.95	64.6±10.6	65.9±8.3	0.32
BMI (kg/m ²)	23.6±3.5	23.5±2.8	0.87	23.2±3.9	22.4±3.3	0.12
Current smoking (%)	10 (26%)	91 (20%)	0.40	6 (11%)	3 (1%)	0.002
HT (%)	21 (54%)	184 (39%)	0.090	24 (45%)	78 (35%)	0.16
DM (%)	10 (26%)	81 (17%)	0.20	9 (17%)	19 (8%)	0.076
DLP (%)	16 (41%)	249 (53%)	0.18	24 (45%)	134 (60%)	0.066
eGFR (mL/min/1.73m ²)	73±19	72±13	0.50	74±17	75±13	0.94
Uric acid (µmol/L)	367±90	351±78	0.23	280±73	270±60	0.21
FPG (mmol/L)	5.6±1.5	5.7±1.0	0.67	5.3±1.1	5.4±0.8	0.35
HbA1c (mmol/mol)	43±11	38±9	0.002	44±11	36±7	< 0.001
HbA1c excluding DM	37±4	34±3	< 0.001	40±4	34±3	< 0.001
patients (mmol/mol)						
LDL-C (mmol/L)	2.9±1.0	3.1±0.7	0.067	3.1±0.8	3.2±0.6	0.19
HDL-C (mmol/L)	1.4±0.4	1.6±0.4	< 0.001	1.5±0.5	1.9±0.5	< 0.001
TG (mmol/L)	1.3(1.0-1.8)	1.1(0.8-1.6)	0.082	1.2(0.9-1.5)	0.9(0.7-1.3)	0.032
CRP (mg/L)	0.60(0.30-1.20)	0.50(0.30-1.00)	0.098	0.80(0.30-1.90)	0.50(0.30-1.00)	0.024
WBC (×10 ⁹ /L)	6.0±1.7	5.6±1.5	0.10	5.5±1.5	5.0±1.2	0.022
RBC (×10 ¹² /L)	4.47±0.32	4.74 ± 0.40	< 0.001	4.16±0.48	4.40±0.31	< 0.001
Hgb (g/L)	140±14	151±11	< 0.001	126±11	135±9	< 0.001
Platelets (×10 ⁹ /L)	203±58	206±4.8	0.72	221±57	217±45	0.60
Proteinuria (%)	3/21 (14%)	7/392 (2%)	0.011	4/37 (11%)	2/206 (1%)	0.006
CFR	1.9±0.9 (n =17)	no data		2.7±0.9 (n =38)	no data	
CFR ≥2.0 (%)	6/17 (35%)	no data		29/38 (76%)	no data	
Medications (on a	admission)					
ACE-I or ARB (%)	18 (46%)	no data		10 (19%)	no data	
CCB (%)	17 (44%)	no data		29 (55%)	no data	
Nitrate (%)	9 (23%)	no data		9 (17%)	no data	
Beta-blocker (%)	16 (41%)	no data		5 (9%)	no data	
Statin (%)	10 (25%)	no data		17 (32%)	no data	

Data are number of patients (%), means ± standard deviation (SD), and medians (interquartile range). MVA, microvascular angina; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; CFR, coronary flow reserve; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.

	Univariate		Multivariate		
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value	
Sex (women)	2.82 (1.81-4.39)	< 0.001	1.64 (0.86-3.14)	0.13	
BMI (per 1 kg/m ²)	1.02 (0.95-1.10)	0.55			
Current smoking	1.34 (0.75-2.39)	0.33			
HT	1.57 (1.01-2.43)	0.044	1.29 (0.73-2.29)	0.38	
DM	1.54 (0.89-2.66)	0.12			
DLP	0.62 (0.40-0.96)	0.032	not selected *		
eGFR (per 1 mL/min/1.73m ²)	1.01 (0.99-1.02)	0.41			
Uric acid (per 1 µmol/L)	1.00 (1.00-1.00)	0.46			
FPG (per 1 mmol/L)	0.80 (0.60-1.06)	0.12			
HbA1c (per 1 mmol/mol)	1.07 (1.04-1.10)	< 0.001	1.07 (1.04-1.10)	< 0.001	
LDL-C (per 1 mmol/L)	0.73 (0.53-1.00)	0.051			
HDL-C (per 1 mmol/L)	0.21 (0.11-0.39)	< 0.001	0.13 (0.06-0.29)	< 0.001	
TG (per 1 mmol/L)	1.09 (0.85-1.39)	0.50			
CRP (per 1 mg/L)	1.06 (0.98-1.15)	0.13			
WBC (per 1×10 ⁹ /L)	1.14 (0.99-1.31)	0.063			
Hgb (per 10×g/L)	0.46 (0.39-0.56)	< 0.001	0.56 (0.44-0.72)	< 0.001	
Platelets (per 10×10^9 /L)	1.01 (0.97-1.06)	0.54			
Proteinuria	8.98 (3.21-25.1)	< 0.001	not selected **		

Table 3. Univariate and Multivariate Logistic Regression Analysis for MVA

* We did not evaluate DLP in the multivariate logistic regression analysis because the correlation between DLP and HDL-C level was strong. ** We did not evaluate 'Proteinuria' in the multivariate logistic regression analysis because the number of patients with proteinuria was low (regarding these contents, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

	Univariate		Multivariate		
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value	
BMI (per 1 kg/m ²)	1.01 (0.90-1.14)	0.87			
Current smoking	1.42 (0.67-3.02)	0.36			
HT	1.79 (0.93-3.45)	0.083			
DM	1.64 (0.77-3.50)	0.20			
DLP	0.61 (0.31-1.18)	0.14			
eGFR (per 1 mL/min/1.73m ²)	1.01 (0.99-1.03)	0.50			
Uric acid (per 1 µmol/L)	1.00 (1.00-1.00)	0.23			
FPG (per 1 mmol/L)	0.93 (0.65-1.32)	0.67			
HbA1c (per 1 mmol/mol)	1.05 (1.02-1.08)	0.004	1.04 (1.00-1.08)	0.034	
LDL-C (per 1 mmol/L)	0.65 (0.41-1.03)	0.068			
HDL-C (per 1 mmol/L)	0.11 (0.04-0.32)	< 0.001	0.10 (0.03-0.34)	< 0.001	
TG (per 1 mmol/L)	1.28 (0.92-1.78)	0.15			
CRP (per 1 mg/L)	1.05 (0.95-1.15)	0.34			
WBC (per 1×10 ⁹ /L)	1.18 (0.97-1.42)	0.10			
Hgb (per 10×g/L)	0.51 (0.39-0.66)	< 0.001	0.64 (0.48-0.87)	0.004	
Platelets (per 10×10 ⁹ /L)	1.00 (0.92-1.06)	0.72			
Proteinuria	9.17 (2.19-34.4)	0.002	not selected *		

Table 4. Univariate and Multivariate Logistic Regression Analysis for MVA in Men

* We did not evaluate 'Proteinuria' in the multivariate logistic regression analysis because the number of patients with proteinuria was low (regarding the content, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

	Univariate		Multivariate		
	Odds Ratio (95%CI)	p value	Odds Ratio (95%CI)	p value	
BMI (per 1 kg/m ²)	1.07 (0.98-1.16)	0.12			
Current smoking	9.45 (2.28-39.1)	0.002	not selected *		
HT	1.56 (0.85-2.86)	0.15			
DM	2.22 (0.94-5.23)	0.069			
DLP	0.56 (0.31-1.03)	0.061			
eGFR (per 1 mL/min/1.73m ²)	1.00 (0.98-1.02)	0.94			
Uric acid (per 1 µmol/L)	1.00 (1.00-1.01)	0.21			
FPG (per 1 mmol/L)	0.87 (0.53-1.25)	0.35			
HbA1c (per 1 mmol/mol)	1.12 (1.07-1.18)	< 0.001	1.09 (1.04-1.15)	0.001	
LDL-C (per 1 mmol/L)	0.74 (0.46-1.17)	0.19			
HDL-C (per 1 mmol/L)	0.12 (0.05-0.29)	< 0.001	0.65 (0.49-0.86)	0.003	
TG (per 1 mmol/L)	1.09 (0.77-1.55)	0.63			
CRP (per 1 mg/L)	1.23 (1.01-1.50)	0.042	0.25 (0.01-10.3)	0.47	
WBC (per 1×10 ⁹ /L)	1.30 (1.04-1.62)	0.024	1.50 (1.03-2.20)	0.037	
Hgb (per 10×g/L)	0.39 (0.28-0.55)	< 0.001	0.41 (0.25-0.65)	< 0.001	
Platelets (per 10×10 ⁹ /L)	1.02 (0.96-1.08)	0.60			
Proteinuria	12.4 (2.18-70.2)	0.005	not selected *		

Table 5. Univariate and Multivariate Logistic Regression Analysis for MVA in Women

* We did not evaluate 'current smoking' and 'proteinuria' in the multivariate logistic regression analysis because the numbers of patients with current smoking or proteinuria were low (regarding these contents, see also Statistical analyses in Methods).

MVA, microvascular angina; CI, confidence interval; BMI, body mass index; HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP, C-reactive protein; WBC, white blood cell; Hgb, haemoglobin.

	Men (n =505)			Women (n =278)		
	MVA (n =39)	Control (n =466)	p value	MVA (n =53)	Control (n =225)	p value
RBC (×10 ¹² /L)	4.47±0.32	4.74±0.40	< 0.001	4.16±0.48	4.40±0.31	< 0.001
Haematocrit (L/L)	0.41 ± 0.04	0.45±0.03	< 0.001	0.38±0.03	0.41±0.03	< 0.001
Hgb (g/L)	140±14	151±11	< 0.001	126±11	135±9	< 0.001
MCV (fL)	91.8±4.0	95.1±3.9	< 0.001	92.0±4.0	93.8±3.9	< 0.001
Serum iron (µmol/L)	20±12	21±7	0.25	16±6	20±6	< 0.001
Ferritin (µg/L)	168±121	139±108	0.26	83±80	75±55	0.62

Table 6. Erythrocyte Indices of MVA in Men and Women

Data are number of patients (%), means ± standard deviation (SD). MVA, microvascular angina; Hgb, haemoglobin; MCV, mean corpuscular volume.

1 Table 7. Clinical Characteristics of 55 MVA Patients Stratified into Those with a CFR

$_2$ <2.0 and Those with a CFR \geq 2.0

3

	CFR <2.0	CFR ≥2.0	
	(n=20)	(n =35)	p value
Age (years)	64.6±12.9	62.3±11.8	0.52
Sex (women), (%)	9 (45%)	29 (83%)	0.006
BMI (kg/m ²)	23.3±4.1	24.0±4.2	0.51
Current smoking (%)	1 (5%)	6 (17%)	0.40
HT (%)	7 (35%)	20 (57%)	0.16
DM (%)	3 (15%)	7 (20%)	0.73
DLP (%)	8 (40%)	18 (51%)	0.56
eGFR (mL/min/1.73m ²)	71±15	73±15	0.72
Uric acid (µmol/L)	297±102	308±67	0.62
FPG (mmol/L)	5.6±1.1	5.3±1.2	0.47
HbA1c (mmol/mol)	42±8	44±12	0.46
HbA1c excluding DM patients (mmol/mol)	39±4	40±4	0.55
LDL-C (mmol/L)	2.8±0.7	3.0±0.8	0.49
HDL-C (mmol/L)	1.5±0.4	1.5±0.5	0.93
TG (mmol/L)	1.2 (0.8-1.6)	1.2 (0.9-1.6)	0.81
CRP (mg/L)	0.30 (0.28-1.33)	0.80 (0.30-1.50)	0.59
WBC (×10 ⁹ /L)	6.1±2.2	5.4±1.2	0.11
RBC (×10 ¹² /L)	4.31 ±0.41	4.32±0.44	0.94
Hgb (g/L)	135±13	133±16	0.62
Platelets (×10 ⁹ /L)	200±65	225±64	0.17
Proteinuria (%)	1/12 (8%)	3/27 (11%)	1.00
Medications (on admission)			
ACE-I or ARB (%)	8 (40%)	10 (29%)	0.55
CCB (%)	10 (50%)	24 (69%)	0.25
Nitrate (%)	5 (25%)	8 (23%)	1.00
Beta-blocker (%)	6 (30%)	6 (17%)	0.32
Statin (%)	9 (45%)	11 (31%)	0.39

4

5 Data are number of patients (%), means ± standard deviation (SD), and medians (interquartile

range). CFR, coronary flow reserve; MVA, microvascular angina; BMI, body mass index;
HT, hypertension; DM, diabetes mellitus; DLP, dyslipidaemia; eGFR, estimated glomerular
filtration rate; FPG, fasting plasma glucose; HbA1c, haemoglobin A1c; LDL-C, low-density
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; CRP,
C-reactive protein; WBC, white blood cell; RBC, red blood cell; Hgb, haemoglobin; ACE-I,
angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium
channel blocker.

8

Figure 1

